Cohen Capital Management Inc. Acquires 184 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Cohen Capital Management Inc. lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 57,528 shares of the medical research company’s stock after purchasing an additional 184 shares during the quarter. Thermo Fisher Scientific comprises about 5.0% of Cohen Capital Management Inc.’s holdings, making the stock its 3rd biggest holding. Cohen Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $29,928,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in TMO. AMF Tjanstepension AB acquired a new stake in shares of Thermo Fisher Scientific during the third quarter worth about $42,409,000. Howard Capital Management Group LLC raised its holdings in Thermo Fisher Scientific by 0.5% in the third quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company’s stock valued at $33,759,000 after acquiring an additional 286 shares in the last quarter. Silver Oak Securities Incorporated raised its holdings in Thermo Fisher Scientific by 8.5% in the third quarter. Silver Oak Securities Incorporated now owns 693 shares of the medical research company’s stock valued at $429,000 after acquiring an additional 54 shares in the last quarter. Joel Isaacson & Co. LLC raised its holdings in Thermo Fisher Scientific by 2.8% in the third quarter. Joel Isaacson & Co. LLC now owns 2,798 shares of the medical research company’s stock valued at $1,731,000 after acquiring an additional 77 shares in the last quarter. Finally, Elwood & Goetz Wealth Advisory Group LLC acquired a new stake in Thermo Fisher Scientific in the third quarter valued at approximately $536,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the topic of several analyst reports. UBS Group raised their target price on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a report on Friday, January 31st. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price on the stock in a report on Friday, January 10th. Scotiabank increased their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a research note on Monday, February 3rd. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Finally, Bank of America dropped their price target on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Four investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $656.86.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the sale, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. The trade was a 26.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the sale, the chief executive officer now owns 111,192 shares of the company’s stock, valued at $58,960,669.92. This trade represents a 8.25 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 20,125 shares of company stock worth $11,231,699. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Trading Down 1.0 %

NYSE:TMO opened at $532.55 on Friday. The company has a market capitalization of $203.70 billion, a PE ratio of 32.22, a price-to-earnings-growth ratio of 2.99 and a beta of 0.77. The stock has a fifty day simple moving average of $548.47 and a 200-day simple moving average of $567.46. Thermo Fisher Scientific Inc. has a 52-week low of $493.30 and a 52-week high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.32%. The ex-dividend date is Friday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.41%.

Thermo Fisher Scientific announced that its board has initiated a share buyback program on Friday, November 15th that allows the company to buyback $4.00 billion in shares. This buyback authorization allows the medical research company to buy up to 2% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its shares are undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.